Navigation Links
Statin does not appear helpful for children with learning disabilities caused by genetic disorder

Use of simvastatin by children with neurofibromatosis type 1 (NF1), a genetic disorder that can cause learning disabilities, did not result in improved cognitive function, according to a study in the July 16 issue of JAMA.

Characteristics of NF1 (incidence 1:3,000) include skin disorders, problems with small and large movement skills as well as the frequent occurrence of cognitive disabilities, such as visual-spatial skills, nonverbal long-term memory and attention span, according to background information in the article. Some NF1 studies involving mice suggested that use of a statin could improve cognitive deficits.

Lianne C. Krab, M.Sc., of Erasmus MC University Medical Center, Sophia Children's Hospital, Rotterdam, The Netherlands, and colleagues conducted a randomized trial to study the effect of the statin simvastatin on cognitive function of 62 children with NF1. The participants received simvastatin or placebo treatment once daily for 12 weeks.

After the treatment period, there was no significant difference between the simvastatin and placebo groups on several cognitive measures (determined by testing), including assessing nonverbal long-term memory, assessing attention and prism adaptation task (measurement of adaptation of the angle of hand movements in response to prism glass distortion, which is thought to be dependent on cerebellar function).

In the secondary outcome measures, the researchers found a significant improvement in the simvastatin group in object assembly scores, which was specifically observed in children with poor baseline performance. Other secondary outcome measures, such as attention fluctuations and a developmental test of visual-motor integration revealed no significant effect of simvastatin treatment.

"The negative outcome of this trial suggests that simvastatin should not be prescribed to ameliorate the cognitive deficits associated with NF1. Further studies to evaluate a longer treatment period and whether the object assembly finding is spurious may be warranted," the authors conclude.


Contact: Ype Elgersma, Ph.D.
JAMA and Archives Journals

Related biology news :

1. Natural compound in broccoli could treat devastating genetic skin disorder
2. Tigers disappear from Himalayan refuge
3. Californias wildflowers are disappearing, new book by UCR ecologist cautions
4. Mars water appears to have been too salty to support life
5. A Great Lakes mystery: The case of the disappearing species
6. Exposure to low levels of radon appears to reduce the risk of lung cancer, new study finds
7. A compound extracted from olives inhibits cancer cells growth and prevents their appearance
8. Wild chimpanzees appear not to regularly experience menopause
9. Humans appear hardwired to learn by over-imitation
10. Laser can spot illness before symptoms appear
11. Scientists identify embryonic stem cells by appearance alone
Post Your Comments:
(Date:10/7/2015)... -- --> --> According ... third quarter 2015 amounted to around 960 MSEK. This exceeds ... was communicated 20 August 2015. --> ... a continued growing demand for the company,s products, the revenues ... than during the third quarter. The revenue guidance for 2015 ...
(Date:10/6/2015)... 2015  Maverix Biomics, Inc., a leading genomic ... software portfolio with the debut of its RNA-Seq ... in eukaryotes. The software is integrated into the ... analysis solution that leverages proven open-source algorithms and ... efforts. Garry Nolan,s laboratory at ...
(Date:10/1/2015)... , Oct. 1, 2015  Biometrics includes diverse ... human body characteristics, such as fingerprints, eye retinas, ... Adoption of biometrics technology has been constantly increasing ... last five years. In addition to the most ... fingerprint recognition, other means of biometric authentication are ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... October 13, 2015 ARRY ), ... (NASDAQ: JUNO ), and Progenix Pharmaceuticals, Inc. (NASDAQ: ... Life Sciences Corp. (OTCQX: AVXLD), Juno Therapeutics, Inc. (NASDAQ: ... PGNX ) --> Cooperative research and development ... can potentially lead to advancements in the treatment of ...
(Date:10/13/2015)... JACKSONVILLE, Florida , October 13, 2015 ... company specializing in the development of innovative peptide and ... & metastatic disease, will be a featured presenting company ... at the Wyndham Grand Hotel in ... --> TapImmune, Inc. (TPIV), a clinical-stage immunotherapy ...
(Date:10/13/2015)... ... October 13, 2015 , ... Clinovo recently appointed Jeff Parr and Ed Donaldson ... clinical data solutions business. , Jeff Parr has spent the past decade providing quality ... Dennison, Thermo Fisher, and Ab Sciex to name a few. He is based ...
(Date:10/13/2015)... the United States , Canada ... 14% of all new cases of kidney cancer.   --> ... and Europe .  PRCC represents about 14% ... Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Hutchison ... ("AstraZeneca") have completed enrolment in a global Phase II study of ...
Breaking Biology Technology: